mTOR and HDAC2 are simultaneously activated during electrically induced kindling of seizures

Natalia Chmielewska1, Adriana Wawer2, Bartosz Osuch1

  • 1Department of Neurochemistry, Institute of Psychiatry and Neurology, Sobieskiego 9 Street, 02-957 Warsaw, Poland.

Epilepsy Research
|August 4, 2022
PubMed

Insights

Neurotrophic and epigenetic pathways are key in epilepsy development. This study found that activating the BDNF/mTOR pathway and HDAC2 system during epileptogenesis suggests a potential for combined therapies.

Area of Science:

  • Neuroscience
  • Epilepsy Research
  • Molecular Biology

Background:

  • Epileptogenesis and epilepsy are linked to neurotrophic and epigenetic pathways.
  • Current therapies targeting these pathways are limited.
  • Key pathways include BDNF-TrkB-mTOR signaling (neurotrophic) and REST/NRSF-coREST-HDAC2 (epigenetic).

Purpose of the Study:

  • To investigate the activation of BDNF-TrkB-mTOR and REST/NRSF-coREST-HDAC2 pathways during epileptogenesis.
  • To assess protein and mRNA levels of key molecules in a rat kindling model.

Main Methods:

  • Utilized an electrical kindling model in rats.
  • Measured protein and mRNA expression of BDNF, TrkB, mTOR, REST/NRSF, coREST, and HDAC2 in brain tissue.

Main Results:

  • Increased BDNF and decreased coREST expression observed in kindled rats.
  • Elevated mTOR and HDAC2 protein levels were found in stimulated animals, but mRNA levels did not correlate.
  • Higher BDNF, mTOR, and HDAC2 expression occurred in rats that did not meet kindling criteria compared to fully kindled rats.

Conclusions:

  • The BDNF/mTOR pathway is primarily activated during epileptogenesis, with less involvement of TrkB.
  • The REST/NRSF transcription factor appears non-critical for HDAC2 activation in this model.
  • Simultaneous activation of mTOR and HDAC2 highlights multifactorial neuronal adaptation, suggesting combined therapies targeting both pathways as a novel strategy for preventing epileptogenesis.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
570
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
268
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
424